AtaiBeckley Inc. (ATAI)
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
- Symbol
- ATAI
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.71B
- 52 week range
- 7.08 - 7.45
Valuation
- Share price
- $7.35 (close of 2026-09-11)
- P/E (TTM)
- -15.98x
- Price to book
- 15.38x
- Price to free cash flow
- -30.60x
- Enterprise value
- $2.55B
- Book value per share
- $0.48
Price performance
| Period | Change |
|---|
| 1 day | 0.00% |
| 5 days | +0.14% |
| 1 month | +1.94% |
| 3 months | +93.42% |
| 6 months | +81.03% |
| Year to date | +79.71% |
| 1 year | +59.78% |
| 3 years | +393.29% |
| 5 years | -55.35% |
| All time | -62.21% |
Profitability and growth
- Return on equity
- -297.32%
- Return on invested capital
- -464.11%
- Return on assets
- -225.49%
- Return on capital employed
- -239.21%
- Net margin
- -16142.02%
- EBITDA margin
- -15726.31%
- Revenue growth
- 1227.60%
- Net income growth
- -342.19%
- Free cash flow growth
- -25.63%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -3.27%
- Current ratio
- 8.58x
- Net debt to EBITDA
- 1.53x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $4.09M
- EBITDA
- $-643.05M
- Net income
- $-660.05M
- Earnings per share
- $-2.91
- Shares outstanding
- 226.53M
Income statement by year
| Period end | Revenue | Net income | EPS |
|---|
| 2025-12-31 | $4.09M | $-660.05M | $-2.91 |
| 2024-12-31 | $308.00K | $-149.27M | $-0.93 |
Margins and returns by year
| Period end | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | -16142.02% | -297.32% | -464.11% |
| 2024-12-31 | -48463.96% | -128.07% | -82.69% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $85.30M | - |
| 2024-12-31 | $17.50M | $14.13M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-103.58M | $14.21M |
| 2024-12-31 | $-82.44M | $25.49M |
Dividend history
- Most recent payment
- 2018-08-27
| Payment date | Dividend per share |
|---|
| 2018-08-27 | $6.00 |
| 2017-06-08 | $0.39 |
| 2014-06-26 | $0.39 |
| 2012-08-16 | $0.15 |
| 2011-06-28 | $0.43 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-05-12 | Mar/2026 | - |
| 2026-03-06 | - | - |
| 2025-11-12 | - | - |
| 2025-08-14 | - | - |
| 2025-05-14 | - | - |
| 2025-03-26 | - | - |
| 2025-03-17 | - | - |
| 2024-11-13 | - | - |
Filings and sources
- Company website
- ataibeckley.com
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades